Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
1 Jun 2025 at 11:57pm
Tarlatamab, a bispecific delta-like ligand 3?directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer ...
The New England Journal of Medicine | Research & Review Articles on ...
8 Jan 2026 at 5:09am
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
22 Apr 2025 at 11:55pm
In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP...
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer
29 May 2025 at 11:54pm
Background First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E?mutated metastatic ...
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
6 Feb 2025 at 11:58pm
Methods In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg on day ...
Phase 3 Trial of Semaglutide in Metabolic Dysfunction?Associated ...
29 Apr 2025 at 11:54pm
Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction?associated steatohepatitis (MASH). In this ongoing phase 3, multicenter ...
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
31 May 2025 at 11:59pm
Methods In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise ...
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung ...
2 Jun 2025 at 2:38pm
Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non?small-cell lung cancer (NSCLC) in a phase 3 ...
Lorundrostat Efficacy and Safety in Patients with Uncontrolled ...
22 Apr 2025 at 11:55pm
Background Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited.
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast ...
30 May 2025 at 11:53pm
In the phase 3, double-blind, randomized INAVO120 trial, treatment with inavolisib plus palbociclib?fulvestrant led to a significant progression-free survival benefit, as compared with placebo ...
WHAT IS THIS? This is an unscreened compilation of results from several search engines. The sites listed are not necessarily recommended by Surfnetkids.com.
1 Jun 2025 at 11:57pm
Tarlatamab, a bispecific delta-like ligand 3?directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer ...
The New England Journal of Medicine | Research & Review Articles on ...
8 Jan 2026 at 5:09am
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
22 Apr 2025 at 11:55pm
In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP...
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer
29 May 2025 at 11:54pm
Background First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E?mutated metastatic ...
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
6 Feb 2025 at 11:58pm
Methods In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg on day ...
Phase 3 Trial of Semaglutide in Metabolic Dysfunction?Associated ...
29 Apr 2025 at 11:54pm
Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction?associated steatohepatitis (MASH). In this ongoing phase 3, multicenter ...
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
31 May 2025 at 11:59pm
Methods In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise ...
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung ...
2 Jun 2025 at 2:38pm
Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non?small-cell lung cancer (NSCLC) in a phase 3 ...
Lorundrostat Efficacy and Safety in Patients with Uncontrolled ...
22 Apr 2025 at 11:55pm
Background Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited.
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast ...
30 May 2025 at 11:53pm
In the phase 3, double-blind, randomized INAVO120 trial, treatment with inavolisib plus palbociclib?fulvestrant led to a significant progression-free survival benefit, as compared with placebo ...
WHAT IS THIS? This is an unscreened compilation of results from several search engines. The sites listed are not necessarily recommended by Surfnetkids.com.
